Clearside BiomedicalCLSD
About: Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
Employees: 32
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
0.54% more ownership
Funds ownership: 11.42% [Q1] → 11.96% (+0.54%) [Q2]
2% less funds holding
Funds holding: 44 [Q1] → 43 (-1) [Q2]
8% less capital invested
Capital invested by funds: $8.09M [Q1] → $7.43M (-$655K) [Q2]
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Yi Chen | 1,141%upside $5 | Neutral Downgraded | 18 Jul 2025 |
Needham Serge Belanger | 645%upside $3 | Hold Downgraded | 17 Jul 2025 |
Financial journalist opinion









